MX2023006290A - Derivados de 2,3-dihidro--benzo[b][1,4]oxazin-4-il)(5-(fenil)-piri din-3- il)metanona y compuestos similares como inhibidores de cyp11a1 para el tratamiento del cáncer de próstata. - Google Patents
Derivados de 2,3-dihidro--benzo[b][1,4]oxazin-4-il)(5-(fenil)-piri din-3- il)metanona y compuestos similares como inhibidores de cyp11a1 para el tratamiento del cáncer de próstata.Info
- Publication number
- MX2023006290A MX2023006290A MX2023006290A MX2023006290A MX2023006290A MX 2023006290 A MX2023006290 A MX 2023006290A MX 2023006290 A MX2023006290 A MX 2023006290A MX 2023006290 A MX2023006290 A MX 2023006290A MX 2023006290 A MX2023006290 A MX 2023006290A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- cyp11a1
- inhibitors
- treatment
- prostate cancer
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 206010060862 Prostate cancer Diseases 0.000 title abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- -1 2,3-dihydro-4h-benzo[b][1,4]oxazin-4-yl Chemical group 0.000 title 2
- 108010084976 Cholesterol Side-Chain Cleavage Enzyme Proteins 0.000 title 1
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical class O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 abstract 1
- 101710198130 NADPH-cytochrome P450 reductase Proteins 0.000 abstract 1
- 108010085012 Steroid Receptors Proteins 0.000 abstract 1
- 102000001307 androgen receptors Human genes 0.000 abstract 1
- 108010080146 androgen receptors Proteins 0.000 abstract 1
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 102000015694 estrogen receptors Human genes 0.000 abstract 1
- 108010038795 estrogen receptors Proteins 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 102000005969 steroid hormone receptors Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20206226 | 2020-12-01 | ||
| PCT/FI2021/050828 WO2022117920A1 (en) | 2020-12-01 | 2021-11-30 | 2,3-dihydro-4h-benzo[b][1,4]oxazin-4-yl)(5-(phenyl)-pyridin-3-yl)methanone derivatives and similar compounds as cyp11a1 inhibitors for the treatment of prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006290A true MX2023006290A (es) | 2023-08-21 |
Family
ID=78827916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006290A MX2023006290A (es) | 2020-12-01 | 2021-11-30 | Derivados de 2,3-dihidro--benzo[b][1,4]oxazin-4-il)(5-(fenil)-piri din-3- il)metanona y compuestos similares como inhibidores de cyp11a1 para el tratamiento del cáncer de próstata. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240124431A1 (https=) |
| EP (1) | EP4255902B1 (https=) |
| JP (1) | JP7824953B2 (https=) |
| KR (1) | KR20230117187A (https=) |
| CN (1) | CN116724034A (https=) |
| AU (1) | AU2021391977A1 (https=) |
| CA (1) | CA3200556A1 (https=) |
| MX (1) | MX2023006290A (https=) |
| WO (1) | WO2022117920A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202409023A (zh) * | 2022-07-14 | 2024-03-01 | 美商富曼西公司 | 除草苯并𠯤 |
| CN121002012A (zh) * | 2023-03-29 | 2025-11-21 | 西藏海思科制药有限公司 | Cyp11a1抑制剂及其用途 |
| CN121039123A (zh) * | 2023-04-21 | 2025-11-28 | 西藏海思科制药有限公司 | Cyp11a1抑制剂及其用途 |
| WO2025021182A1 (en) * | 2023-07-27 | 2025-01-30 | Acerand Therapeutics (Hong Kong) Limited | Cyp11a1 inhibitors |
| WO2025051216A1 (zh) * | 2023-09-08 | 2025-03-13 | 深圳众格生物科技有限公司 | 一种cyp11a1抑制剂、其制备方法及其应用 |
| WO2025168117A1 (zh) * | 2024-02-08 | 2025-08-14 | 盛睿泽华医药科技（苏州）有限公司 | 一种多环化合物及其制备方法和应用 |
| WO2026002207A1 (en) * | 2024-06-28 | 2026-01-02 | Acerand Therapeutics (Hong Kong) Limited | Heterocyclic compounds as cyp11a1 inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8759379B2 (en) * | 2008-01-04 | 2014-06-24 | Gilead Sciences, Inc. | Inhibitors of cytochrome P450 |
| AR110412A1 (es) | 2016-12-22 | 2019-03-27 | Orion Corp | Inhibidores de la cyp11a1 |
-
2021
- 2021-11-30 US US18/255,218 patent/US20240124431A1/en active Pending
- 2021-11-30 MX MX2023006290A patent/MX2023006290A/es unknown
- 2021-11-30 JP JP2023533363A patent/JP7824953B2/ja active Active
- 2021-11-30 CA CA3200556A patent/CA3200556A1/en active Pending
- 2021-11-30 KR KR1020237022283A patent/KR20230117187A/ko active Pending
- 2021-11-30 AU AU2021391977A patent/AU2021391977A1/en active Pending
- 2021-11-30 CN CN202180080720.1A patent/CN116724034A/zh active Pending
- 2021-11-30 WO PCT/FI2021/050828 patent/WO2022117920A1/en not_active Ceased
- 2021-11-30 EP EP21823336.9A patent/EP4255902B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022117920A1 (en) | 2022-06-09 |
| EP4255902A1 (en) | 2023-10-11 |
| CA3200556A1 (en) | 2021-11-30 |
| JP2023551340A (ja) | 2023-12-07 |
| KR20230117187A (ko) | 2023-08-07 |
| EP4255902B1 (en) | 2025-06-04 |
| JP7824953B2 (ja) | 2026-03-05 |
| AU2021391977A1 (en) | 2023-07-13 |
| AU2021391977A9 (en) | 2024-08-01 |
| US20240124431A1 (en) | 2024-04-18 |
| CN116724034A (zh) | 2023-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023006290A (es) | Derivados de 2,3-dihidro--benzo[b][1,4]oxazin-4-il)(5-(fenil)-piri din-3- il)metanona y compuestos similares como inhibidores de cyp11a1 para el tratamiento del cáncer de próstata. | |
| MX2025000642A (es) | Compuestos macrociclicos para el tratamiento de cancer | |
| AU2004257696B2 (en) | Use of parthenolide derivatives as antileukemic and cytotoxic agents | |
| AU2006218711A2 (en) | Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity | |
| ZA200505273B (en) | Novel compound | |
| ZA202212150B (en) | Tricyclic compounds as egfr inhibitors | |
| EA032467B1 (ru) | Нестероидные антиандрогены и селективные модуляторы андрогеновых рецепторов с пиридильной группой | |
| IL97122A (en) | 7-Transformed androstane-) or androstine- (3,71-dions, useful as aromatase inhibitors, and pharmaceuticals containing them | |
| IL159254A0 (en) | Hetero-bicyclic crf antagonists | |
| Moreira et al. | Synthesis of novel C17 steroidal carbamates: Studies on CYP17 action, androgen receptor binding and function, and prostate cancer cell growth | |
| ATE397609T1 (de) | Corticotropinfreisetzungsfaktor antagonisten | |
| PE20240217A1 (es) | Preparacion de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2 | |
| DE60144246D1 (de) | Imidazolderivate, verfahren zu deren herstellung und deren verwendung | |
| WO2009083272A3 (de) | 19-NOR-STEROIDDERIVATE MIT EINER 15α,16α-METHYLENGRUPPE UND EINEM GESÄTTIGTEN 17,17-SPIROLACTONRING, DEREN VERWENDUNG SOWIE DIESE DERIVATE ENTHALTENDE ARZNEIMITTEL | |
| MX2025013420A (es) | Compuestos novedosos como inhibidores de cyp11a1 y metodos para uso de ellos | |
| Shirazi et al. | Synthesis and characterization of epoxide impurities of abiraterone acetate | |
| Crooks et al. | Use of parthenolide derivatives as antileukemic and cytotoxic agents | |
| Ibrahim-Ouali et al. | New synthesis of pentacyclic steroids by stereoselective epoxide ring opening | |
| MX2023004108A (es) | Derivados de benzo[h]quinazolin-4-amina y tieno[3,2-h]quinazolin-4 -amina para el tratamiento del cáncer. | |
| Sedighi et al. | In vivo evaluation of the aromatase inhibition by 4‑((1H‑imidazol‑1‑yl) methyl)‑2‑(4‑fluorophenyl)‑8‑phenylquinoline | |
| Khandelwal | Unfolding the Hsp90 Foldasome: Structure-Activity Relationship Studies on EGCG and Development of Isoform-Selective Inhibitors | |
| HK1088845B (en) | Use of parthenolide derivatives as antileukemic and cytotoxic agents |